Paratek Pharmaceuticals, Inc. Files for a $92 Million IPO
9/28/2012 6:33:43 AM
BOSTON, Sept. 27, 2012 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Paratek. The number of shares to be offered and the price range for the offering have not yet been determined.
UBS Investment Bank and Leerink Swann LLC will act as the joint bookrunning managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department, 888-827-7275, or Leerink Swann LLC, Attention: Syndicate Prospectus Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, by telephone at 800-808-7525, or by facsimile at 617-918-4900.
Paratek is a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The Company's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious community-acquired bacterial infections.
CONTACT: Kathryn M. Boxmeyer, Vice President & CFO, Paratek Pharmaceuticals, Inc., +1-617-275-0040 ext. 238, email@example.com; Kathy Galante, Burns McClellan, Inc. for Paratek Pharmaceuticals, Inc., +1-212-213-0006, firstname.lastname@example.org
SOURCE Paratek Pharmaceuticals, Inc.